Nov 2, 2007 by Brian LawlerFlamel Plays Close to the VestShould you join the game without the cards on the table?
Nov 1, 2007 by Brian LawlerAchtung, GPC!Negative news on a cancer treatment sinks this biotech's shares.
Oct 31, 2007 by Brian LawlerSanofi: Stable, for NowThe drugmaker's healthy Q3 results shine amid slumping competitors.
Oct 31, 2007 by Brian LawlerThe Next Hepatitis C Blockbuster?Drugmakers race to develop the next billion-dollar treatment. Place your bets.
Oct 31, 2007 by Brian LawlerAdams On-and-Off With the FDAA new compound gets delayed, but the drugmaker still raises earnings.
Oct 31, 2007 by Brian LawlerNastech Still BreathingComing phase 2 results will help investors assess how well its drugs might sell.
Oct 30, 2007 by Brian LawlerImClone OnwardGlobal sales lift ImClone's third-quarter financial results.
Oct 30, 2007 by Brian LawlerViroPharma Gets No RespectThe Q3 report shows declining numbers, but there's more to the story.
Oct 29, 2007 by Brian LawlerWorld's Scariest Stock: DendreonDendreon's scary future should make it an "underperform" in CAPS.
Oct 29, 2007 by Brian LawlerAmgen RevisitedQ3 financials fail to impress, but there was good news, too.
Oct 29, 2007 by Brian LawlerBetter Late Than Never for PanacosPanacos announces new data for its lead drug.
Oct 29, 2007 by Brian LawlerQLT in a Rut or Ready for a Comeback?QLT updates investors on its top drugs.
Oct 29, 2007 by Brian LawlerMedicines Stopping the BleedingThe drugmaker outlines plans to grow its top and bottom lines.
Oct 29, 2007 by Brian LawlerCelgene Shares Shouldn't Be on SaleThe change in its guidance doesn't rate the drop in its stock price.
